Directa Plus – others are now joining the “Italian statutory auditors” on the pitch, they think it’s all over…

Most recently on company describing itself as “one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets” Directa Plus (DCTA), I wrote ‘the “Italian statutory auditors” are on the pitch, they think it’s all over…’ including concluding is a £2.5 million funding facility from an investor really going to be made available here? Instead it’s hopefully my prior warnings were indeed heeded. Now “Appointment of Administrators”…

Directa Plus (#DCTA) – “at this time… the potential funding facility principal… is not capable of being progressed”

Directa Plus – the “Italian statutory auditors” are on the pitch, they think it’s all over…

Most recently on company describing itself as “one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets” Directa Plus (DCTA), last month with the shares further falling to 7.5p I wrote ‘“funding facility… advanced discussions”, but on what terms and hadn’t it said similar already recently?’ and concluded that hopefully my prior warnings were heeded and, natch, still a sell. What about now a further announcement; “Update on Further Funding”?

Directa Plus – “funding facility… advanced discussions”, but on what terms and hadn’t it said similar already recently?…

Directa Plus (DCTA) has announced that it “is in advanced discussions with an institutional investor for the provision of an up to £2.5m funding facility to extend the company’s cash runway”. However, its most recent close market cap was below £9 million, so is that why it’s “institutional investor” which dares not speak its name and haven’t I recently already heard something similar from this self-described “leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”?

Directa Plus (#DCTA) – “advanced discussions with an institutional investor for the provision of an up to £2.5m funding facility”, though “at this time there can be no certainty”

Directa Plus – “advanced” loan discussions, and CFO “to step down”…

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has issued an “Update on Funding and Board change” announcement and with the shares, already down from above 20p reached earlier this month, now a further more than 11% down to 12p, what’s the details of the company’s “update”?

Directa Plus – Full year trading and operational update, “a solid financial base”?…

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets” Directa Plus (DCTA) has issued a “Full year trading and operational update” including stating “c.30% improvement year on year, underpinned by disciplined cost control and operational efficiencies” and “a solid financial base going forward”. So why a share price fall to 12.5p?

Directa Plus (#DCTA) FY broadly in line, warns needs funding in 202366, chairman walks - another happy day on the AIM Casino

Directa Plus – interims, is it really “laying the foundations for sustainable long-term growth”?…

Describing itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced its results for the first half of the 2025 calendar year including “revenue increased 15% to €3.90m… remains confident that FY25 will deliver a material year-on-year EBITDA improvement, laying the foundations for sustainable long-term growth”. With the shares currently down at 10.25p in response, how “sustainable” do its foundations currently look?

Directa Plus – states its trading “demonstrates the effectiveness of our strategic focus and disciplined cost management”. Er, does it?!…

Describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, Directa Plus (DCTA) has issued a trading update it states “demonstrates the effectiveness of our strategic focus and disciplined cost management” and noting “continued contract wins across our key markets, operational efficiencies, and targeted capital investment… significant and promising pipeline of opportunities”. So what about a currently still around 10p share price, well below levels reached in June?

Directa Plus – results argue trading “robust”, but what does that mean for the bottom-line?

Describing itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets”, Directa Plus (DCTA) has now announced results for the 2024 calendar year and commences its “Outlook” with that “trading in Q1 FY2025 has been robust”, continuing “momentum building with new contract wins and renewals, and a clear focus on reducing the group’s cost structure. The board is confident in achieving results for FY25 in line with market expectations”. How does that compare with a current 7.3p share price, £7.6 million market capitalisation?

Directa Plus – notes 2024 loss with “positive start to FY2025”. How “positive” really though?…

Describing itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets”, Directa Plus (DCTA) has issued a “Trading and Operational Update & Notice of Results” announcement commencing that “Q1 FY2025 has been robust, with revenues of approximately €2 million, up c. 40% from the same period in 2024” and also including its “current order book stands at approximately €7 million for FY2025, supported further by a good pipeline of opportunities”. So what of a share price, at 6.25p, still well down from 8p as recently as earlier this year?

Directa Plus (#DCTA) – argues trading “momentum” but from an even adjusted LBITDA

Directa Plus – argues “seeing traction build in Environmental contracts”, but how’s the funding?

Describing itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets”, Directa Plus (DCTA) has announced “a new contract win and a renewal” and a “growing pipeline of opportunities”. What about those with the shares currently responding more than 8% higher to 6.5p?

Directa Plus – interims, hopefully my prior warnings were heeded as even its argued “we have been prudent” hasn’t been “prudent” enough!

Most recently writing on company describing itself as “a leading producer and supplier of graphene-based products for use in consumer and industrial markets” Directa Plus (DCTA), in June I concluded with the shares down to 17.5p that I could understand shareholders frustration and suggested whatever the outcome of the General Meeting later in the week, at a £11.6 million market cap, a hopefully prior warnings here were heeded, still, avoid/sell. The shares most recently closed at 16p, and what of now half-year results and the shares currently further down to 11.5p?

Directa Plus – proposed equity raise trouble though the prospective funds for ‘investment in growth opportunities’, right?

Earlier this month Directa Plus (DCTA) announced an equity raise with Chairman Richard Hickinbotham stating that it “will enable the company to accelerate… progress by providing funds for investment in what the board considers to be exciting opportunities. We look forward to beginning the next phase of growth”. Today though an announcement including that “the company has been notified that certain existing shareholders, with a combined shareholding of approximately 19.82 per cent of the company, intend to vote against the Resolutions”. What of this and a current more than 10% lower share price response to 17.5p?

Directa Plus (#DCTA) – shareholders with 19.82% intend to vote against fundraising resolutions, argues such “action jeopardises the future viability of the business”

Directa Plus – hopefully my warning was heeded as it’s now a discounted equity raise…

Most recently writing on Directa Plus (DCTA), describing itself as “a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets”, I wrote in April as the shares rose above 20p on the back of a “GiPave installed at Imola Circuit”-titled announcement, RNS Reach attempted ramptastic?. Today an ‘equity raise’ announcement.

Directa Plus (#DCTA) – proposes to raise up to £6.9m at 18p per share

Directa Plus – “GiPave installed at Imola Circuit”, RNS Reach attempted ramptastic?

Directa Plus (DCTA) states that it “is pleased to announce the installation of GiPave at the Imola Circuit ahead of the upcoming Emilia-Romagna Grand Prix in May 2024 as part of the Formula 1 World Championship, making it the first circuit to feature green, sustainable and high-tech asphalt utilising graphene and recycled plastic”. With GiPave including graphene supplied by Directa Plus, how ‘pleasing’ is the news for shareholders here?